At a glance
- Originator EA Pharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Chemokine CX3CL1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 01 Aug 2018 Discontinued - Phase-I for Inflammatory bowel disease in Japan (PO) (Eisai pipeline, August 2018)
- 21 Jun 2018 EA Pharma terminates a phase I trial (In volunteers) in Japan (PO) (JapicCTI-173779)
- 01 Dec 2017 EA Pharma initiates a phase I trial (in volunteers) in Japan (PO) (JapicCTI-173779)